Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.22
-0.0800-0.52%
Post-market: 15.260.0400+0.26%16:48 EDT
Volume:6.14M
Turnover:94.06M
Market Cap:3.07B
PE:-18.42
High:15.63
Open:15.53
Low:15.12
Close:15.30
52wk High:16.20
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:1.73
T/O Rate:3.14%
Dividend:1
Dividend Rate:6.57%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:0.99
PE(LYR):-10.64

Loading ...

DIARY-Federal Reserve Events

Reuters
·
Mar 27

Park Hotels & Resorts Is Maintained at Hold by Truist Securities

Dow Jones
·
Mar 26

Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

Dow Jones
·
Mar 26

Press Release: MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 26

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire
·
Mar 26

Truist Raises Price Target on Park Hotels & Resorts to $12 From $11, Keeps Hold Rating

MT Newswires Live
·
Mar 26

Press Release: Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

Dow Jones
·
Mar 26

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

GlobeNewswire
·
Mar 25

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Mar 24

Hoth Therapeutics’ HT-001 shows positive PK, safety and clinical activity

TIPRANKS
·
Mar 24

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

prnewswire
·
Mar 24

Press Release: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Dow Jones
·
Mar 19

Which App to Choose for Stock Account Opening? Ultimate Comparison of Ten Platforms Reveals Top Performer

Deep News
·
Mar 19

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

GlobeNewswire
·
Mar 18

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire
·
Mar 18

Capacity Comparison Among Five Major Power Generation Giants' Flagship Listed Companies

Deep News
·
Mar 14

Park Hotels & Resorts schedules first-quarter 2026 earnings conference call

Reuters
·
Mar 14

Vivesto Advances Cantrixil With First Dogs Dosed in PK/Toxicology Study

TIPRANKS
·
Mar 13

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire
·
Mar 13

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

GlobeNewswire
·
Mar 13